Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.

Atsushi TakedaRyosuke TakahashiYoshio TsuboiMasahiro NomotoTetsuya MaedaAkihisa NishimuraKazuo YoshidaNobutaka Hattori

Published in: Movement disorders : official journal of the Movement Disorder Society (2020)

In Japanese patients, both opicapone 25 and 50 mg were significantly more effective than placebo with no dose-dependent difference in efficacy, and both doses were well tolerated. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

double blind
phase iii
placebo controlled
open label
clinical trial
phase ii
randomized controlled trial
study protocol